Related news from |
Fri, 22 Mar 2024 20:00:00 +0000 |
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 13,020 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx E
|
Wed, 20 Mar 2024 12:11:45 +0000 |
10 NASDAQ Stocks with Biggest Upside
In this article, we discuss the 10 NASDAQ stocks with the biggest upside. To skip our detailed analysis, go directly to the 5 NASDAQ Stocks with Biggest Upside. The Nasdaq Composite was the worst performer among the major market indices in 2022 and made a stellar comeback in 2023. The index was down 33% at […]
|
Tue, 12 Mar 2024 21:00:38 +0000 |
Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ...
Thomas Kassberg, the Chief Business Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), has sold 11,509 shares of the company on March 11, 2024, according to a recent SEC filing.
|
Mon, 11 Mar 2024 19:00:51 +0000 |
Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE)
Director Matthew Fust has sold 12,195 shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on March 7, 2024, according to a recent SEC filing.
|
Fri, 08 Mar 2024 14:38:44 +0000 |
10 Biotech Stocks with Huge Potential
In this article, we will take a look at the 10 biotech stocks with huge potential. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Biotech Stocks with Huge Potential. Recent developments, technological as well as optimism related to interest rate reductions, have led to […]
|
Tue, 27 Feb 2024 21:30:00 +0000 |
Ultragenyx to Participate at Investor Conferences in March
44th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management will be participating in three upcoming investor confere
|
Sat, 17 Feb 2024 13:23:41 +0000 |
Ultragenyx Pharmaceutical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
Ultragenyx Pharmaceutical ( NASDAQ:RARE ) Full Year 2023 Results Key Financial Results Revenue: US$434.2m (up 20% from...
|
Fri, 16 Feb 2024 15:43:35 +0000 |
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript February 15, 2024 Ultragenyx Pharmaceutical Inc. beats earnings expectations. Reported EPS is $-1.52, expectations were $-1.65. Ultragenyx Pharmaceutical Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome […]
|
Fri, 16 Feb 2024 15:35:33 +0000 |
Q4 2023 Ultragenyx Pharmaceutical Inc Earnings Call
Q4 2023 Ultragenyx Pharmaceutical Inc Earnings Call
|
Fri, 16 Feb 2024 12:53:00 +0000 |
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
|
Thu, 15 Feb 2024 21:01:00 +0000 |
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
2023 Total Revenue of $434 million, Crysvita® revenue of $328 million and Dojolvi® revenue of $71 million 2024 Financial Guidance: Total Revenue between $500 million and $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 million to $80 million Year-end 2023 cash balance of $777 million and 2024 guidance for Net Cash Used in Operations expected to be less than $400 million NOVATO, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NAS
|
Tue, 13 Feb 2024 18:36:15 +0000 |
15 Best Strong Buy Stocks To Invest In
In this piece, we will take a look at the 15 best strong buy stocks to invest in. If you want to skip our overview of analyst ratings and the finance industry, then you can take a look at the 5 Best Strong Buy Stocks To Invest In. The financial services industry is one of […]
|
Thu, 08 Feb 2024 21:00:00 +0000 |
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
NOVATO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 15, 2024, to discuss its financial results and corporate update for the fourth quarter and the year ending December 31, 2023. The live and replayed webcast of the call w
|
Tue, 06 Feb 2024 13:00:00 +0000 |
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
The latest data from the pivotal Transpher A and long-term follow-up studies will be presented at WORLDSymposium™ 2024NOVATO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced data demonstrating treatment with UX111 (ABO-102) AAV gene therapy resulted in rapid and sustained decreased levels of heparan sulfate (HS) in cerebrospinal fluid (CSF) in patients with Sanfilippo syndrome type A (MPS IIIA), and that sustained reduction in CSF HS exposu
|
Mon, 05 Feb 2024 21:05:00 +0000 |
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
GTX-102 is the first Angelman syndrome therapeutic candidate to receive PRIME designation Phase 1/2 study fully enrolled; expansion data expected in first half of 2024 NOVATO, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to GTX-102 for the treatment of Angelman syndrome (AS). GTX-102 is an investigational antisense oligonucleotide delivered via int
|
Thu, 25 Jan 2024 21:05:00 +0000 |
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of Stage 2 to follow in the second half of 2024 NOVATO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been dosed with UX701 across the three dose-escalation cohorts in Stage 1 of its pivotal Phase 1/2/3 Cyprus2+ study. The company's investigational AAV9 gene therapy is designed to deliver stable expression
|
Thu, 18 Jan 2024 19:41:00 +0000 |
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
Ultragenyx Pharm stock just cleared that benchmark with an upgrade from 75 to 83. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. Is Ultragenyx Pharm Stock A Buy?
|
Thu, 18 Jan 2024 10:39:58 +0000 |
We're Keeping An Eye On Ultragenyx Pharmaceutical's (NASDAQ:RARE) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|
Tue, 09 Jan 2024 23:20:53 +0000 |
After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is Bright
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
|
Mon, 08 Jan 2024 17:18:00 +0000 |
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
Ultragenyx (RARE) reports preliminary full-year 2023 revenues, along with business updates, and shares 2024 revenue guidance.
|